COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies - 1st Edition - ISBN: 9780128164075

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies

1st Edition

0.0 star rating Write a review
Series Volume Editor: Benjamin Bonavida
Hardcover ISBN: 9780128164075
Imprint: Academic Press
Published Date: 1st December 2020
Page Count: 250
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  1. Introduction
    2. Sensitization by Radiotherapy for Rituximab Mediated Cytotoxicity
    3. Sensitization by Bortexomib for Rituximab Mediated Cytotoxicity
    4. Sensitization by Complement Inhibitor for Rituximab-Mediated Cytotoxicity
    5. Sensitization by Immunomodulation Agents for Rituximab-Mediated Cytotoxicity
    6. Combination of Obinutuzumab and Rituximab for Rituximab-Mediated Cytotoxicity
    7. Inhibitor of Tumor Suppressors for Sensitization to Rituximab-Mediated Cytotoxicity
    8. Sensitization Fusion Protein Containing Anti-CD20 Antibody
    9. Inhibitors of Cell Signaling for Sensitization to Rituximab for Rituximab-Mediated Cytotoxicity
    10. Sensitization by Anti-Apoptotic Inhibitors to Rituximab-Mediated Cytotoxicity
    11. Sensitization by Chemotherapy to Rituximab-Mediated Cytotoxicity
    12. Sensitization by HDAC Inhibitors to Rituximab-Mediated Cytotoxicity

Description

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies.

There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors.

This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies.

Key Features

  • Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance
  • Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments
  • Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Readership

Cancer researchers; medical oncologists; clinicians; pharmacologists; translational investigators


Details

No. of pages:
250
Language:
English
Copyright:
© Academic Press 2021
Published:
1st December 2020
Imprint:
Academic Press
Hardcover ISBN:
9780128164075

Ratings and Reviews


About the Series Volume Editor

Benjamin Bonavida

Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press (“Cancer Sensitizing Agents for Chemotherapy,” “Breaking Cancer Resistance to Therapeutic Antibodies,” and “Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.

Affiliations and Expertise

Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA